These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 6600630)
1. [Effect of the joint use of BCG and antithymocyte serum on the growth of a syngeneic tumor in mice]. Babadzhanov AS; Slavina EG Biull Eksp Biol Med; 1983 Feb; 95(2):68-70. PubMed ID: 6600630 [TBL] [Abstract][Full Text] [Related]
2. [Inhibition of the growth of a syngeneic weakly immunogenic tumor in mice resulting from exposures affecting T lymphocyte activity]. Babadzhanov AS; Buntsevich AM Biull Eksp Biol Med; 1983 Apr; 95(4):69-71. PubMed ID: 6338967 [TBL] [Abstract][Full Text] [Related]
3. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. Fujimoto S; Greene MI; Sehon AH J Immunol; 1976 Mar; 116(3):791-9. PubMed ID: 1082894 [TBL] [Abstract][Full Text] [Related]
4. [Cancer and BCG]. Rumi LS Acta Physiol Lat Am; 1981; 31(1):25-34. PubMed ID: 7187581 [TBL] [Abstract][Full Text] [Related]
5. [Effect of sensitization and delayed hypersensitivity reaction on tumor growth in mice]. Polushkin BV; Gordienko SM Vopr Onkol; 1980; 26(7):51-6. PubMed ID: 7405105 [TBL] [Abstract][Full Text] [Related]
6. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism]. Kosugi A; Fujiwara H; Hamaoka T Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750 [TBL] [Abstract][Full Text] [Related]
7. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma. Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061 [TBL] [Abstract][Full Text] [Related]
10. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316 [TBL] [Abstract][Full Text] [Related]
11. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874 [TBL] [Abstract][Full Text] [Related]
12. Modulation of cell-mediated alloimmunity by BCG. II. Induction of specific, nonadherent, non-T-killer cells by BCG and alloantigen. Murahata RI; Mitchell MS J Natl Cancer Inst; 1982 Sep; 69(3):613-8. PubMed ID: 6810008 [TBL] [Abstract][Full Text] [Related]
13. Regulatory role of T lymphocytes and NK cells in tumor allograft development. Sobotková E; Nouza K Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778 [TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of immunity to intraocular tumors in mice. Niederkorn JY; Streilein JW Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767 [TBL] [Abstract][Full Text] [Related]
16. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy. Adler A; Altbaum I J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275 [TBL] [Abstract][Full Text] [Related]
17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
18. Comparative study on antitumor effect of cell-wall skeleton of Mycobacterium bovis BCG and Nocardia rubra, with reference to T-cell dependency and independency. Yanagawa E; Yasumoto K; Ohta M; Nomoto K; Azuma I; Yamamura Y Gan; 1979 Apr; 70(2):141-6. PubMed ID: 381087 [TBL] [Abstract][Full Text] [Related]
19. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
20. [BCG-induced production of a factor inhibiting macrophage migration and growth of melanoma B16]. Gankovskaia LV; Pyl'nova TI; Sokolova EV; Koval'chuk LV Biull Eksp Biol Med; 1980 Sep; 90(9):346-8. PubMed ID: 7000202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]